Amalgamated Bank Has $1.37 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Amalgamated Bank lessened its holdings in Natera, Inc. (NASDAQ:NTRAFree Report) by 1.9% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,787 shares of the medical research company’s stock after selling 426 shares during the period. Amalgamated Bank’s holdings in Natera were worth $1,365,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. American Century Companies Inc. raised its holdings in shares of Natera by 115.7% in the 3rd quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company’s stock worth $73,203,000 after purchasing an additional 887,409 shares during the period. Invesco Ltd. raised its holdings in shares of Natera by 52.0% in the 3rd quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company’s stock worth $111,930,000 after purchasing an additional 865,404 shares during the period. Avidity Partners Management LP raised its holdings in shares of Natera by 107.7% in the 3rd quarter. Avidity Partners Management LP now owns 899,000 shares of the medical research company’s stock worth $39,781,000 after purchasing an additional 466,100 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Natera by 291.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 423,080 shares of the medical research company’s stock worth $26,502,000 after purchasing an additional 314,935 shares during the period. Finally, Jennison Associates LLC bought a new stake in shares of Natera in the 4th quarter worth approximately $13,330,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling

In related news, insider Daniel Rabinowitz sold 30,000 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $104.59, for a total value of $3,137,700.00. Following the completion of the transaction, the insider now directly owns 204,495 shares of the company’s stock, valued at $21,388,132.05. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CFO Michael Burkes Brophy sold 1,866 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $93.97, for a total value of $175,348.02. Following the completion of the transaction, the chief financial officer now directly owns 67,542 shares of the company’s stock, valued at $6,346,921.74. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Daniel Rabinowitz sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $104.59, for a total transaction of $3,137,700.00. Following the transaction, the insider now directly owns 204,495 shares of the company’s stock, valued at approximately $21,388,132.05. The disclosure for this sale can be found here. Insiders sold a total of 410,750 shares of company stock valued at $35,002,520 over the last three months. Corporate insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of analyst reports. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price on the stock in a report on Friday, April 5th. Raymond James lowered shares of Natera from a “strong-buy” rating to an “outperform” rating and upped their target price for the stock from $68.00 to $85.00 in a research report on Tuesday, February 20th. Piper Sandler upped their target price on shares of Natera from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Tuesday. The Goldman Sachs Group upped their target price on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, April 15th. Finally, BTIG Research upped their target price on shares of Natera from $100.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.47.

Check Out Our Latest Research Report on NTRA

Natera Stock Up 2.1 %

Shares of NASDAQ:NTRA opened at $105.52 on Wednesday. The company has a 50-day moving average price of $92.94 and a 200-day moving average price of $72.63. The company has a quick ratio of 3.96, a current ratio of 4.12 and a debt-to-equity ratio of 0.36. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $108.32.

Natera (NASDAQ:NTRAGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The firm had revenue of $367.70 million during the quarter, compared to the consensus estimate of $316.31 million. During the same period in the prior year, the firm posted ($1.23) earnings per share. The company’s quarterly revenue was up 52.1% compared to the same quarter last year. Equities research analysts expect that Natera, Inc. will post -2.35 earnings per share for the current year.

Natera Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

See Also

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.